Document is current
Any future updates will be listed below
-
Authors
Saito, Toshie
Wei, Yue
Wen, Li
Srinivasan, Chaitanya
Wolthers, Benjamin O.
Tsai, Cheng-Yu
Harris, Marian H.
Stevenson, Kristen
Byersdorfer, Craig
Oparaji, Judy-April
Fernandez, Christian
Mukherjee, Amitava
Abu-El-Haija, Maisam
Agnihotri, Sameer
Schmiegelow, Kjeld
Showalter, Megan R.
Fogle, Paul W.
McCulloch, Scott
Contrepois, Kevin
Silverman, Lewis B.
Ding, Ying
Husain, Sohail Z. https://orcid.org/0000-0003-3012-1308
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (DK093491)
Servier
- License Information
-
More Information
Article History
Received: 8 February 2021
Accepted: 15 June 2021
First Online: 27 June 2021
Declarations
:
: S.Z.H has equity in Prevcon and serves on the Scientific Advisory Board for Atias. All other authors have no conflict of interest.
: De-identified serum samples were obtained from patients enrolled in one of two consecutive clinical trials conducted by the Dana-Farber Cancer Institute (DFCI) ALL Consortium; these trials were the DFCI 05–001 and DFCI 11–001. The protocols were approved by the Institutional Review Boards of each participating institution.
: Written informed consent from each participant's parent/legal guardian, as well as patient assent when appropriate, was obtained prior to enrollment and initiation of therapy. Serum samples were obtained only from participants who had consented to the collection and storage of an extra volume of blood for future research.
: All the authors approved the final edited version of this manuscript.
